HC Wainwright Reiterates Buy Rating for Longeveron (NASDAQ:LGVN)

HC Wainwright restated their buy rating on shares of Longeveron (NASDAQ:LGVN) in a report released on Monday,Benzinga reports. They currently have a $10.00 target price on the stock. HC Wainwright also issued estimates for Longeveron’s Q4 2024 earnings at ($0.40) EPS, FY2024 earnings at ($2.83) EPS, Q1 2025 earnings at ($0.40) EPS, Q2 2025 earnings at ($0.34) EPS, Q3 2025 earnings at ($0.35) EPS, Q4 2025 earnings at ($0.37) EPS and FY2025 earnings at ($1.46) EPS.

Separately, Maxim Group dropped their price objective on shares of Longeveron from $15.00 to $6.00 and set a “buy” rating for the company in a research note on Tuesday, August 27th.

Longeveron Stock Up 3.0 %

Shares of LGVN stock opened at $2.06 on Monday. The stock has a market cap of $30.56 million, a P/E ratio of -0.33 and a beta of 0.36. Longeveron has a fifty-two week low of $0.77 and a fifty-two week high of $23.90. The business has a fifty day simple moving average of $2.02 and a 200-day simple moving average of $2.13.

Longeveron (NASDAQ:LGVN) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.34) EPS for the quarter, beating analysts’ consensus estimates of ($0.53) by $0.19. The firm had revenue of $0.77 million for the quarter, compared to analysts’ expectations of $0.34 million. Longeveron had a negative net margin of 967.49% and a negative return on equity of 142.43%. During the same period in the prior year, the company earned ($2.80) EPS. On average, sell-side analysts anticipate that Longeveron will post -3.72 earnings per share for the current year.

Institutional Trading of Longeveron

A number of large investors have recently made changes to their positions in LGVN. Renaissance Technologies LLC purchased a new position in Longeveron in the 2nd quarter valued at about $236,000. State Street Corp purchased a new stake in shares of Longeveron during the third quarter worth about $29,000. Finally, Geode Capital Management LLC raised its position in shares of Longeveron by 316.0% in the third quarter. Geode Capital Management LLC now owns 128,947 shares of the company’s stock valued at $250,000 after buying an additional 97,953 shares during the last quarter. Institutional investors and hedge funds own 10.01% of the company’s stock.

Longeveron Company Profile

Longeveron Inc, a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company’s lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors.